Alector Inc
ALEC
View Detailed Chart
2.015USD
-0.105-4.95%
Market hours （ET）Quotes delayed by 15 min
137.76MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.95%
5 Days
-1.71%
1 Month
-17.08%
6 Months
-33.93%
Year to Date
+29.17%
1 Year
+56.20%
View Detailed Chart
TradingKey Stock Score of Alector Inc
Currency: USD Updated: 2026-03-27Key Insights
Alector Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 139 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 2.88.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alector Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Alector Inc Highlights
StrengthsRisks
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Growing
The company is in a growing phase, with the latest annual income totaling USD 21.05M.
Overvalued
The company’s latest PE is -1.44, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 90.03M shares, increasing 10.00% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 23.10K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.92.
Analyst Rating
Based on
8
analysts
Hold
Current Rating
2.880
Target Price
+35.85%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Alector Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alector Inc Info
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Ticker SymbolALEC
CompanyAlector Inc
CEORosenthal (Arnon)
Websitehttps://alector.com
Related Instruments
-0.67%
-0.92%
+0.66%
+5.97%
-1.17%
+0.67%
+1.39%
-0.80%
-0.09%
+1.90%
-2.83%
+0.47%
+0.85%
+0.46%
-3.06%
0.00%
+0.21%
-0.80%
+2.39%
+1.16%Popular Symbols
247.180
-1.620 (-0.65%)
166.810
-0.710 (-0.42%)
67247.040
+662.990 (+1.00%)
254.790
-18.560 (-6.79%)
2061.150
+61.150 (+3.06%)
360.367
-1.463 (-0.40%)
4531.960
+39.440 (+0.88%)
102.552
+1.943 (+1.93%)
1.146
-0.004 (-0.38%)
159.465
-0.787 (-0.49%)
